O	0	6	Effect
O	7	9	of
O	10	11	a
O	12	17	mixed
O	18	26	solution
O	27	29	of
B-intervention	30	36	sodium
I-intervention	37	48	hyaluronate
I-intervention	49	52	and
I-intervention	53	66	carboxymethyl
I-intervention	67	76	cellulose
O	77	79	on
B-condition	80	85	upper
I-condition	86	90	limb
I-condition	91	102	dysfunction
O	103	108	after
O	109	114	total
O	115	125	mastectomy
O	125	126	:
O	127	128	a
O	129	135	double
O	135	136	-
O	136	141	blind
O	141	142	,
O	143	153	randomized
O	154	162	clinical
O	163	168	trial
O	168	169	.

O	170	180	Restricted
O	181	189	shoulder
O	190	198	mobility
O	199	201	is
O	202	203	a
O	204	209	major
O	210	215	upper
O	216	220	limb
O	221	232	dysfunction
O	233	240	related
O	241	243	to
O	244	249	lower
O	250	257	quality
O	258	260	of
O	261	265	life
O	266	269	and
O	270	280	disability
O	281	286	after
O	287	293	breast
O	294	300	cancer
O	301	308	surgery
O	308	309	.

O	310	312	We
O	313	325	hypothesized
O	326	330	that
O	331	337	sodium
O	338	349	hyaluronate
O	349	350	-
O	350	363	carboxymethyl
O	364	373	cellulose
O	374	375	(
O	375	377	HA
O	377	378	-
O	378	381	CMC
O	381	382	)
O	383	390	applied
O	391	393	to
O	394	397	the
O	398	405	surface
O	406	408	of
O	409	412	the
O	413	423	pectoralis
O	424	429	major
O	430	436	muscle
O	437	442	after
O	443	453	mastectomy
O	454	459	would
O	460	473	significantly
O	474	480	reduce
O	481	485	pain
O	486	489	and
O	490	497	improve
O	498	503	range
O	504	506	of
O	507	513	motion
O	514	515	(
O	515	518	ROM
O	518	519	)
O	520	522	of
O	523	526	the
O	527	535	shoulder
O	536	538	in
O	539	545	breast
O	546	552	cancer
O	553	561	patients
O	561	562	.

O	563	565	We
O	566	575	conducted
O	576	577	a
O	578	584	double
O	584	585	-
O	585	590	blind
O	590	591	,
O	592	602	randomized
O	603	613	controlled
O	614	619	study
O	620	622	to
O	623	631	evaluate
O	632	635	the
O	636	644	clinical
O	645	653	efficacy
O	654	657	and
O	658	664	safety
O	665	667	of
O	668	670	HA
O	670	671	-
O	671	674	CMC
O	675	677	in
O	678	681	the
O	682	692	prevention
O	693	695	of
O	696	701	upper
O	702	706	limb
O	707	718	dysfunction
O	719	724	after
O	725	730	total
O	731	741	mastectomy
O	742	743	(
O	743	745	TM
O	745	746	)
O	746	747	.

O	748	749	A
O	750	755	total
O	756	758	of
B-total-participants	759	761	99
O	762	767	women
O	768	772	with
O	773	779	breast
O	780	786	cancer
O	787	791	were
O	792	800	randomly
O	801	809	assigned
O	810	812	to
O	813	816	one
O	817	819	of
O	820	823	two
O	824	830	groups
O	830	831	.

O	832	834	In
O	835	838	the
O	839	841	HA
O	841	842	-
O	842	845	CMC
O	846	851	group
O	852	853	(
O	853	854	n
O	855	856	=
B-intervention-participants	857	859	50
O	859	860	)
O	860	861	,
O	862	863	a
O	864	869	mixed
O	870	872	HA
O	872	873	-
O	873	876	CMC
O	877	880	was
O	881	888	applied
O	889	891	to
O	892	895	the
O	896	903	surface
O	904	906	of
O	907	910	the
O	911	921	pectoralis
O	922	927	major
O	928	931	and
O	932	940	serratus
O	941	949	anterior
O	950	956	muscle
O	957	962	after
O	963	965	TM
O	965	966	.

O	967	969	In
O	970	973	the
B-control	974	981	control
I-control	982	987	group
O	988	989	(
O	989	990	n
O	991	992	=
B-control-participants	993	995	49
O	995	996	)
O	996	997	,
O	998	1000	TM
O	1001	1004	was
O	1005	1014	performed
B-control	1015	1022	without
I-control	1023	1026	the
I-control	1027	1030	use
I-control	1031	1033	of
I-control	1034	1036	HA
I-control	1036	1037	-
I-control	1037	1040	CMC
O	1040	1041	.

O	1042	1045	The
O	1046	1053	primary
O	1054	1062	outcomes
O	1063	1067	were
B-outcome-Measure	1068	1071	ROM
I-outcome-Measure	1072	1074	of
I-outcome-Measure	1075	1078	the
I-outcome-Measure	1079	1087	shoulder
O	1088	1091	and
B-outcome-Measure	1092	1098	motion
I-outcome-Measure	1098	1099	-
I-outcome-Measure	1099	1106	related
I-outcome-Measure	1107	1111	pain
O	1112	1120	assessed
O	1121	1126	using
O	1127	1128	a
O	1129	1136	numeric
O	1137	1143	rating
O	1144	1149	scale
O	1150	1158	measured
O	1159	1165	before
O	1166	1173	surgery
O	1174	1175	(
O	1175	1177	T0
O	1177	1178	)
O	1179	1182	and
O	1183	1184	3
O	1185	1186	(
O	1186	1188	T1
O	1188	1189	)
O	1190	1193	and
O	1194	1195	6
O	1196	1202	months
O	1203	1204	(
O	1204	1206	T2
O	1206	1207	)
O	1208	1213	after
O	1214	1221	surgery
O	1221	1222	.

O	1223	1232	Secondary
O	1233	1241	outcomes
O	1242	1250	included
B-outcome-Measure	1251	1263	disabilities
I-outcome-Measure	1264	1266	of
I-outcome-Measure	1267	1270	the
I-outcome-Measure	1271	1274	arm
I-outcome-Measure	1274	1275	,
I-outcome-Measure	1276	1284	shoulder
I-outcome-Measure	1284	1285	,
I-outcome-Measure	1286	1289	and
I-outcome-Measure	1290	1294	hand
I-outcome-Measure	1295	1296	(
I-outcome-Measure	1296	1300	DASH
I-outcome-Measure	1300	1301	)
O	1302	1305	and
O	1306	1309	the
B-outcome-Measure	1310	1320	pectoralis
I-outcome-Measure	1321	1326	minor
I-outcome-Measure	1327	1333	length
I-outcome-Measure	1334	1338	test
O	1338	1339	.

O	1340	1348	Compared
O	1349	1353	with
O	1354	1357	the
O	1358	1365	control
O	1366	1371	group
O	1371	1372	,
O	1373	1376	the
O	1377	1379	HA
O	1379	1380	-
O	1380	1383	CMC
O	1384	1389	group
O	1390	1396	showed
O	1397	1404	greater
B-outcome	1405	1415	reductions
I-outcome	1416	1418	in
I-outcome	1419	1432	postoperative
I-outcome	1433	1444	restriction
I-outcome	1445	1447	of
I-outcome	1448	1453	total
I-outcome	1454	1462	shoulder
I-outcome	1463	1466	ROM
O	1467	1468	(
O	1468	1471	sum
O	1472	1474	of
O	1475	1482	flexion
O	1483	1486	and
O	1487	1497	horizontal
O	1498	1507	abduction
O	1507	1508	)
O	1509	1511	at
O	1512	1513	3
O	1514	1520	months
O	1521	1522	(
O	1522	1524	10
O	1524	1525	.
O	1525	1527	20
O	1527	1528	Â°
O	1528	1529	,
O	1530	1531	P
O	1532	1533	=
O	1534	1535	0
O	1535	1536	.
O	1536	1539	004
O	1539	1540	)
O	1540	1541	.

B-outcome	1542	1546	Mean
I-outcome	1547	1551	pain
I-outcome	1552	1558	levels
O	1559	1566	related
O	1567	1569	to
O	1570	1577	flexion
O	1578	1581	and
O	1582	1592	horizontal
O	1593	1602	abduction
O	1603	1607	were
O	1608	1621	significantly
O	1622	1627	lower
O	1628	1630	in
O	1631	1634	the
O	1635	1637	HA
O	1637	1638	-
O	1638	1641	CMC
O	1642	1647	group
O	1648	1649	(
B-iv-cont-mean	1649	1650	-
I-iv-cont-mean	1650	1651	1
I-iv-cont-mean	1651	1652	.
I-iv-cont-mean	1652	1654	32
O	1655	1658	and
B-cv-cont-mean	1659	1660	-
I-cv-cont-mean	1660	1661	0
I-cv-cont-mean	1661	1662	.
I-cv-cont-mean	1662	1664	93
O	1664	1665	,
O	1666	1678	respectively
O	1678	1679	,
O	1680	1681	P
O	1682	1683	<
O	1684	1685	0
O	1685	1686	.
O	1686	1688	05
O	1688	1689	)
O	1689	1690	.

O	1691	1694	The
B-outcome	1695	1699	DASH
I-outcome	1700	1705	score
O	1706	1709	was
O	1710	1715	lower
O	1716	1717	(
O	1717	1718	-
O	1718	1719	4
O	1719	1720	.
O	1720	1722	94
O	1722	1723	;
O	1724	1725	P
O	1726	1727	=
O	1728	1729	0
O	1729	1730	.
O	1730	1733	057
O	1733	1734	)
O	1735	1737	in
O	1738	1741	the
O	1742	1744	HA
O	1744	1745	-
O	1745	1748	CMC
O	1749	1754	group
O	1755	1757	at
O	1758	1760	T2
O	1760	1761	.

O	1762	1764	No
B-outcome	1765	1772	adverse
I-outcome	1773	1779	effect
O	1780	1783	was
O	1784	1792	observed
O	1793	1795	in
O	1796	1802	either
O	1803	1808	group
O	1808	1809	.

O	1810	1815	These
O	1816	1823	results
O	1824	1831	provide
O	1832	1840	evidence
O	1841	1845	that
O	1846	1848	HA
O	1848	1849	-
O	1849	1852	CMC
O	1853	1856	may
O	1857	1864	provide
O	1865	1869	pain
O	1870	1876	relief
O	1877	1880	and
O	1881	1888	improve
O	1889	1892	ROM
O	1893	1895	of
O	1896	1899	the
O	1900	1908	shoulder
O	1909	1916	without
O	1917	1924	causing
O	1925	1932	adverse
O	1933	1940	effects
O	1940	1941	.

O	1942	1945	The
O	1946	1952	effect
O	1953	1955	on
O	1956	1966	pectoralis
O	1967	1976	tightness
O	1977	1983	should
O	1984	1986	be
O	1987	1999	investigated
O	2000	2002	in
O	2003	2010	further
O	2011	2018	studies
O	2018	2019	.
